19 December 2018 - MSD’s Keytruda has been given a green light for use within the EU as an adjuvant treatment for stage III melanoma, and has also been made available on the NHS.

NICE has recommended the drug’s use within the cancer drugs fund as monotherapy for the adjuvant treatment of adults with stage III melanoma with lymph node involvement who have undergone complete resection.

Melanoma patients are currently only monitored to see if their cancer returns, known as the “watch and wait” approach, at which point the cancer has often already progressed, so this approval is a fantastic milestone towards more appropriate treatment.

Read Pharma Times article